Juan Diaz, DO
Infectious Disease · Altamonte Springs, FLNPI 1831272061
Payments from drug & device makers
Across 1,496 payments — averaging $655.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$283K
- Shionogi Inc$170K
- Merck$147K
- Melinta Therapeutics, LLC$121K
- Takeda Pharmaceuticals U.S.A., Inc.$117K
- La Jolla Pharmaceutical Company$81K
- plus $61K from 18 others
What the payments were for
- Consulting fees$26,0903%
- Speaking & faculty fees$811,44183%
- Travel & lodging$108,95311%
- Food & beverage$32,7703%
- Education$6580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 408 | $283,030 |
| Shionogi Inc | 205 | $170,285 |
| Merck | 209 | $146,733 |
| Melinta Therapeutics, LLC | 206 | $121,411 |
| Takeda Pharmaceuticals U.S.A., Inc. | 145 | $116,782 |
| La Jolla Pharmaceutical Company | 95 | $80,827 |
| Insmed, Inc. | 112 | $37,136 |
| Tetraphase Pharmaceuticals, Inc. | 29 | $17,908 |
| Ferring Pharmaceuticals Inc. | 4 | $2,004 |
| Cipla USA Inc. | 4 | $1,624 |
| Astellas Pharma US Inc | 25 | $908 |
| Paratek Pharmaceuticals, Inc. | 14 | $464 |
| Gilead | 7 | $245 |
| Johnson & Johnson | 16 | $172 |
| Aimmune Therapeutics, Inc. | 3 | $89 |
| Kerecis Limited | 3 | $86 |
| Janssen Products, LP | 1 | $50 |
| Mayne Pharma Commercial LLC | 3 | $42 |
| Shire North American Group Inc | 2 | $27 |
| Accelerate Diagnostics Inc. | 1 | $26 |
| Smith+Nephew | 1 | $24 |
| GSK | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$979,913 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 17 | $34,528 |
| MicafunginMicafungin Sodium | 14 | $15,749 |
| ErtapenemErtapenem Sodium | 20 | $10,379 |
| CeftriaxoneCeftriaxone Sodium | 67 | $9,800 |
| Meropenem | 23 | $5,266 |
| Valganciclovir Hcl | 19 | $4,944 |
| Cefepime Hcl | 14 | $3,884 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 12 | $3,134 |
| CefuroximeCefuroxime Axetil | 57 | $1,775 |
| Minocycline Hcl | 12 | $984 |
| Cefdinir | 30 | $871 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 40 | $562 |
| Acyclovir | 19 | $276 |
| Fluconazole | 11 | $256 |
| Ciprofloxacin Hcl | 28 | $248 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Altamonte Springs
- Christopher CooperAltamonte Springs$278K
- Jason SniffenAltamonte Springs$175K
- Moti RamgopalFort Pierce$13.5M
- Larry BushAtlantis$9.3M
- Olayemi OsiyemiWest Palm Beach$8.8M
- Charlotte-Paige RolleOrlando$6M
- Edwin DejesusOrlando$5.9M
- Dushyantha JayaweeraMiami$5.1M
- Federico HinestrosaOrlando$5.1M
- Godson OguchiOrange City$5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.